Puma Biotechnology, Inc. (PBYI) stock
PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)
Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –
Puma Biotechnology r&d expenses
Research and development expenses are spending on new products and technology.
Puma Biotechnology's R&D Expenses for the twelve months ending Jun 30, 2026 was $71.44M, up 25.3% year over year. For fiscal 2025 it was $62.07M, up 13.0% from the year before. Over ten years it grew -11.4% a year on average. The highest annual figure on record is $222.80M in fiscal 2016.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.07M | +13.0% |
| FY2024 | Dec 31, 2024 | $54.94M | +9.0% |
| FY2023 | Dec 31, 2023 | $50.38M | -3.6% |
| FY2022 | Dec 31, 2022 | $52.24M | -27.3% |
| FY2021 | Dec 31, 2021 | $71.87M | -26.4% |
| FY2020 | Dec 31, 2020 | $97.65M | -26.5% |
| FY2019 | Dec 31, 2019 | $132.85M | -19.4% |
| FY2018 | Dec 31, 2018 | $164.85M | -20.7% |
| FY2017 | Dec 31, 2017 | $207.81M | -6.7% |
| FY2016 | Dec 31, 2016 | $222.80M | +6.9% |
| FY2015 | Dec 31, 2015 | $208.47M | +69.6% |
| FY2014 | Dec 31, 2014 | $122.92M | +172.9% |
| FY2013 | Dec 31, 2013 | $45.05M | -9.2% |
| FY2012 | Dec 31, 2012 | $49.64M | +5909.2% |
| FY2011 | Dec 31, 2011 | $826.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $18.90M | +22.3% |
| Q1 FY2026 | Mar 31, 2026 | $19.80M | +42.8% |
| Q4 FY2025 | Dec 31, 2025 | $16.84M | +11.0% |
| Q3 FY2025 | Sep 30, 2025 | $15.91M | +26.8% |
| Q2 FY2025 | Jun 30, 2025 | $15.45M | +13.4% |
| Q1 FY2025 | Mar 31, 2025 | $13.86M | +2.0% |
| Q4 FY2024 | Dec 31, 2024 | $15.17M | +17.8% |
| Q3 FY2024 | Sep 30, 2024 | $12.55M | +9.6% |
| Q2 FY2024 | Jun 30, 2024 | $13.63M | +2.1% |
| Q1 FY2024 | Mar 31, 2024 | $13.59M | +6.9% |
| Q4 FY2023 | Dec 31, 2023 | $12.87M | -6.6% |
| Q3 FY2023 | Sep 30, 2023 | $11.45M | +1.7% |
| Q2 FY2023 | Jun 30, 2023 | $13.36M | +11.6% |
| Q1 FY2023 | Mar 31, 2023 | $12.71M | -16.6% |
| Q4 FY2022 | Dec 31, 2022 | $13.78M | -2.7% |
| Q3 FY2022 | Sep 30, 2022 | $11.25M | -40.3% |
| Q2 FY2022 | Jun 30, 2022 | $11.97M | -35.8% |
| Q1 FY2022 | Mar 31, 2022 | $15.24M | -24.7% |
| Q4 FY2021 | Dec 31, 2021 | $14.17M | -41.4% |
| Q3 FY2021 | Sep 30, 2021 | $18.84M | -19.3% |
| Q2 FY2021 | Jun 30, 2021 | $18.64M | -24.5% |
| Q1 FY2021 | Mar 31, 2021 | $20.23M | -20.5% |
| Q4 FY2020 | Dec 31, 2020 | $24.16M | -20.1% |
| Q3 FY2020 | Sep 30, 2020 | $23.34M | -22.3% |
| Q2 FY2020 | Jun 30, 2020 | $24.69M | -33.0% |
| Q1 FY2020 | Mar 31, 2020 | $25.46M | -28.8% |
| Q4 FY2019 | Dec 31, 2019 | $30.24M | -21.1% |
| Q3 FY2019 | Sep 30, 2019 | $30.03M | -17.4% |
| Q2 FY2019 | Jun 30, 2019 | $36.86M | -14.8% |
| Q1 FY2019 | Mar 31, 2019 | $35.73M | -23.9% |
| Q4 FY2018 | Dec 31, 2018 | $38.33M | -23.7% |
| Q3 FY2018 | Sep 30, 2018 | $36.36M | -26.5% |
| Q2 FY2018 | Jun 30, 2018 | $43.25M | -18.8% |
| Q1 FY2018 | Mar 31, 2018 | $46.93M | -14.4% |
| Q4 FY2017 | Dec 31, 2017 | $50.25M | -10.9% |
| Q3 FY2017 | Sep 30, 2017 | $49.50M | -4.8% |
| Q2 FY2017 | Jun 30, 2017 | $53.25M | – |
| Q1 FY2017 | Mar 31, 2017 | $54.80M | – |
| Q4 FY2016 | Dec 31, 2016 | $56.40M | – |
| Q3 FY2016 | Sep 30, 2016 | $51.98M | – |
See a number that looks wrong?